1. Introduction {#sec1}
===============

Osteoporosis is a metabolic bone disease that is characterized by decreased bone mass and a high risk of fracture, even after relatively minor falls \[[@B1]\]. Bone mineral density (BMD) is a parameter commonly used to measure bone strength and serves as a reliable indicator of osteoporosis. Higher body weight has been identified as a factor that is conducive to maintaining BMD \[[@B2]--[@B4]\]. While this association between obesity and BMD is widely recognized, there is still a disagreement regarding the impact of fat mass on bones \[[@B5]--[@B7]\]. Evidence has shown that body fat may have different effects on the BMD, depending on the region of deposition; this regional variation in the manner in which fat mass influences bone density may be attributed to the differences in the effects of subcutaneous fat and visceral adipose tissue (VAT) on bones. For example, in young, healthy men, trunk fat, rather than appendicular fat, is negatively correlated with cortical bone size \[[@B8]\]. Further, subcutaneous fat has been shown to have a positive correlation with the structure and strength of bones in females \[[@B9], [@B10]\]. A prospective cohort study revealed that excess visceral fat is associated with a high risk of nonspinal fractures in nonobese elderly women \[[@B11]\]. Moreover, Ng et al. found that this association was stronger among postmenopausal women \[[@B12]\].

Adult growth hormone deficiency (AGHD) is an endocrinal disorder caused by multiple factors, mainly pituitary tumors and/or their treatment \[[@B13]\]. When AGHD remains untreated, patients exhibit increased fat mass, especially visceral fat, and they have an increased risk of fractures \[[@B14]\]. Fleseriu et al. have shown that AGHD patients have a 2--5-fold increase in the risk of fracture \[[@B15]\]. The severity of GHD has a direct impact on the degree of bone loss and fracture risk. It compromises the patient\'s health-related quality of life and contributes to morbidity. Therefore, it is important to understand and evaluate the impact of AGHD on body composition. Although some studies have investigated the role of body composition in regulating bone density \[[@B16], [@B17]\], data on these mechanisms in AGHD patients are limited. Further investigations are necessary to understand the relationship between total fat mass, visceral fat, and BMD in AGHD patients.

Considering the lack of current knowledge in the manner in which fat mass (FM), especially visceral fat, contributes to BMD, we sought to examine the possible relationships between body composition parameters and BMD in AGHD patients.

2. Materials and Methods {#sec2}
========================

2.1. Participants {#sec2.1}
-----------------

We enrolled 57 patients (38 females and 19 males) diagnosed with AGHD in this study. The diagnosis of GHD in all the cases was established using the insulin tolerance test (ITT), which is the gold standard for the diagnosis of AGHD. All patients were investigated at the First Affiliated Hospital of Chongqing Medical University between February 2009 and December 2018. Patients who met the following criteria were excluded from the study: (1) levels of other pituitary hormone maintained within the normal reference range for at least the previous six months; (2) history of other systemic illness or medications known to affect bone metabolism, such as hyperthyroidism, rheumatoid arthritis, severe liver and kidney disease, and oral bisphosphonates; (3) history of musculoskeletal diseases, heart diseases, malignant tumor, or mental disorder; (4) state of pregnancy or lactation. All participants provided written informed consent, and the study protocol was approved by the ethics committee of the First Affiliated Hospital of Chongqing Medical University.

2.2. Anthropometry and Biochemical Measurements {#sec2.2}
-----------------------------------------------

All subjects underwent measurement of height, body weight, waist circumference, hip circumferences, and blood pressure test using the standard clinical procedures, while wearing light clothing and no shoes. Height and waist and hip circumferences were measured up to the nearest 0.1 cm, while body weight was determined with an accuracy of ±0.1 kg.

The patients were required to fast overnight, and their venous blood samples were collected to measure the values of the following biochemical parameters: fasting plasma glucose (FPG), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein (LDL-C). All the biochemical variables were determined by an automatic biochemical assay (Type 7600, Hitachi Ltd, and Japan). As per the guidelines for the prevention and treatment of dyslipidemia in Chinese adults, dyslipidemia was defined by the following: serum TG level of ≥1.70 mmol/L, serum TC level of ≥5.18 mmol/L, serum LDL-C level of ≥3.37 mmol/L, or serum HDL-C level of \<1.04 mmol/L \[[@B18]\].

2.3. Assessment of Bone Mineral Density and Body Composition {#sec2.3}
------------------------------------------------------------

Measurements of FM, VATM, and BMD of the lumbar spine (L1-L4) were obtained by a DXA system (Hologic Discovery QDR® Series, Bedford, MA, USA), which is a reliable tool for detecting osteoporosis. The device used was calibrated every morning, and its coefficient of variation (CV) for bone measurements was less than 1%. In addition, a whole body scan was performed with DXA to determine the FM and VATM, with a CV of \<2.3%. BMD was expressed as T-score, and it was calculated by the National Health and Nutrition Examination Survey database, as provided by the manufacturer. According to the World Health Organization (WHO) guidelines, patients were classified into three categories by their T-score: T-score of ≥−1.0 standard deviations (SD), normal; T-score between −2.5 SD and −1.0 SD, with osteopenia, and T-score of ≤−2.5 SD, osteoporosis \[[@B19]\].

All the procedures employed in this study were consistent with the ethical standards of the First Affiliated Hospital of Chongqing Medical University and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

2.4. Index Calculation {#sec2.4}
----------------------

BMI = weight (kg)/height (m)^2^

Waist-to-hip ratio (WHR) = waist circumference (cm)/hip circumference (cm).

2.5. Statistical Analyses {#sec2.5}
-------------------------

Data for continuous variables were represented as means ± standard deviation or medians (interquartile range), as appropriate. The variables were compared using the independent samples *t*-test and Mann--Whitney *U* test. The relationships between various demographic and laboratory parameters pertaining to BMD were assessed by linear correlation and linear regression. Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) 17.0 (SPSS Inc., Chicago, IL). A *P* value (2-tailed) of \<0.05 was considered significant.

3. Results {#sec3}
==========

The clinical and biochemical characteristics of male and female patients with AGHD are presented in [Table 1](#tab1){ref-type="table"}. The values of BMI, WC, WHR, and VATM were significantly higher in men than in women (all *P* \< 0.05), whereas the values of BMD were higher in women than in men (*P* \< 0.05). No such sex-based differences were noted in terms of age, SBP, DBP, FPG, TC, TG, HDL-C, LDL-C, and FM. Further, the incidence of hypertension (defined by a history of hypertension or systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg) was 39.5% in women and 36.8% in men. Diabetes, which was defined by a history of diabetes or fasting plasma glucose level of FPG ≥7.0 mmol/L, was confirmed in 15.8% and 21.1% of the female and male patients, respectively. As per the criteria defined for Chinese individuals, the incidence of dyslipidemia was 52.6% and 42.1% according to serum TG levels, 26.3% and 21.1% according to serum TC levels, 31.6% and 26.3% according to serum LDL-C levels, and 39.5% and 36.8% according to serum HDL-C levels, in women and men, respectively.

Of the 57 AGHD subjects, 5 (8.8%; male *n* = 0, female *n* = 5) were normal, while 21 (36.8%; male *n* = 5, female *n* = 16) had osteopenia and 31 (54.4%; male *n* = 14, female *n* = 17) had osteoporosis according to their *T*-score values. Accordingly, male and female patients were classified into those with osteoporosis and those without osteoporosis (normal subjects and patients with osteopenia) ([Table 2](#tab2){ref-type="table"}). Intriguingly, only female AGHD patients with osteoporosis had significantly higher values of FM and VATM, as compared to those without osteoporosis (both *P* \< 0.05). On the other hand, male AGHD patients with osteoporosis had higher LDL-C values than those without osteoporosis.

Simple correlations between the various variables and BMD values were then derived by the Pearson correlation analysis. As shown in [Table 3](#tab3){ref-type="table"}, the parameters of age, BMI, FM, and VATM showed a negative correlation with BMD in female patients with AGHD (all *P* \< 0.05). However, no significant correlation between BMD and other variables was noted in male patients with AGHD.

Therefore, BMD was regarded as a dependent variable. [Table 4](#tab4){ref-type="table"} shows the results of multiple linear stepwise regression analysis of the relationship between the independent variables and BMD by gender. The analysis demonstrated that VATM was closely associated with the BMD in females, even after correcting for other covariates, including age, BMI, and FM.

4. Discussion {#sec4}
=============

This study was mainly aimed at investigating the relationship between the parameters indicating body composition and BMD in AGHD patients. Our major findings are as follows: first, AGHD patients had a considerably high incidence of risk factors of cardiovascular diseases, such as diabetes, hypertension, and hypertriglyceridemia. Second, the prevalence of low BMD was very high among AGHD patients. Third, only in female AGHD patients, the values of FM and VATM were significantly higher in patients with osteoporosis than in those without osteoporosis. Fourth, multiple linear regression analysis revealed that VATM was independently correlated to the BMD in female with AGHD.

AGHD patients are known to have a high risk of cardiovascular diseases \[[@B20]--[@B22]\]. This was also confirmed in our study. These results highlight the importance of screening AGHD patients for cardio-metabolic risk factors.

Apart from promoting growth, GH is known to affect body composition via various mechanisms such as glycolipid metabolism as well as bone formation and remodeling \[[@B23]\]. GH promotes the longitudinal bone growth in children and plays an important role in bone mass maintenance in adults. In addition, GH stimulates the activity of chondrocytes and osteoblasts and influences the proliferation and differentiation of their precursors \[[@B24], [@B25]\]. Furthermore, GH regulates the secretion of parathyroid hormone, thereby affecting bone remodeling. The development and function of several skeletal cell lineages are also regulated by insulin-like growth factor 1 (IGF-1) \[[@B26], [@B27]\]. Our findings suggest that patients with AGHD have low BMD and a high incidence of osteoporosis. Therefore, both the prevention and treatment of osteoporosis are important in AGHD patients to reduce the resultant morbidity and mortality.

In this study, we found that FM, VATM, and BMD correlated significantly in female AGHD patients, but not in male patients. The association between FM and BMD has been confirmed in several studies \[[@B28]--[@B30]\]. Moreover, the marked sex differences in the impact of FM on BMD have also been reported previously. In addition, the association between fat tissue and BMD has been shown to exist only in females, not in male. These sex-based discrepancies can be attributed to the differences in the sex hormone levels of males and females \[[@B31], [@B32]\]. Further, the association between FM and BMD in females may be due to the changes in the biomechanical forces and the increased levels of endogenous estrogen in women with higher FM. These higher levels of endogenous estrogen are the result of the aromatization of androgen to weak estrogen in subcutaneous fat tissue \[[@B33], [@B34]\]. The differential effect of fat distribution on BMD has been shown in several previous studies \[[@B35]--[@B37]\]. Patients with AGHD often exhibit central obesity, which is mainly caused by an increase in visceral fat. Put together, these findings explain why FM is negatively correlated with BMD in women with AGHD. Our study also revealed an inverse association between VATM and BMD in female patients with AGHD.

Our study has a few limitations. The present study has a cross-sectional design, which does not allow for the analysis of the causal relationships among the various parameters assessed. Therefore, long-term investigations are necessary to elucidate the changes in the relationship between body composition and bone density in an individual. Another limitation of our study is that the relatively small number of patients enrolled in study could affect the external validity. More large-scale studies are therefore warranted to confirm our findings.

In conclusion, we found that VATM is closely correlated with the BMD in women with AGHD. These results suggest that the accumulation of visceral adipose tissue might disrupt the bone homeostasis in this specific subpopulation.
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###### 

Clinical and biochemical characteristics by gender.

  Characteristics   Male                 Female               *P* value
  ----------------- -------------------- -------------------- -------------
  Age (years)       55.63 ± 15.14        52.84 ± 13.96        0.498
  BMI (kg/m^2^)     25.16 ± 4.06         22.81 ± 3.41         **0.026**
  WC (cm)           92.55 ± 9.93         81.87 ± 8.53         **\<0.001**
  WHR               0.93 ± 0.05          0.88 ± 0.06          **0.004**
  SBP (mmHg)        120.95 ± 22.96       124.27 ± 18.62       0.323
  DBP (mmHg)        82.58 ± 13.60        74.81 ± 14.41        0.057
  FPG (mmol/L)      6.01 ± 1.83          6.10 ± 2.12          0.961
  TC (mmol/L)       4.48 ± 1.16          4.75 ± 1.73          0.552
  TG (mmol/L)       1.59 (0.87--2.34)    1.64 (1.09--3.08)    0.630
  HDL-C (mmol/L)    1.15 ± 0.44          1.39 ± 0.53          0.299
  LDL-C (mmol/L)    2.75 ± 1.18          3.12 ± 1.33          0.334
  FM (g)            22050.13 ± 7371.52   19133.73 ± 6553.14   0.155
  VATM (g)          705.56 ± 270.37      480.91 ± 253.43      **0.005**
  BMD (T-score)     −2.74 ± 0.91         −2.12 ± 0.94         **0.021**

Data are expressed as the mean ± standard deviation (SD) or median (interquartile range). The values of parameters showing significant differences between the two genders are in bold (*P* \< 0.05). *N* = 57 patients (38 females and 19 males). T-score of BMD was determined for the lumbar spine, at L1-4.

###### 

Comparison of characteristics between the N-OP and OP groups by gender.

  Characteristics Male   N-OP                 OP                   *P* value
  ---------------------- -------------------- -------------------- -------------
  *N*                    5                    14                    
  Age (years)            56.00 ± 9.95         55.50 ± 16.93        0.952
  BMI (kg/m2)            23.05 ± 2.43         25\. 91 ± 4.32       0.182
  WC (cm)                86.20 ± 4.21         94.82 ± 10.50        0.096
  WHR                    0.90 ± 0.03          0.94 ± 0. 06         0.156
  SBP (mmHg)             133.00 ± 12.10       128.86 ± 26.08       0.740
  DBP (mmHg)             93.20 ± 9.18         78.79 ± 13.09        0.138
  FPG (mmol/L)           6.30 ± 2.46          5.92 ± 1.76          0.767
  TC (mmol/L)            3.80 ± 0.54          4.67 ± 1.23          0.193
  TG (mmol/L)            0.64 (0.49--2.28)    1.74 (1.07--2.51)    0.347
  HDL-C (mmol/L)         1.30 ± 0.43          1.11 ± 0.44          0.443
  LDL-C (mmol/L)         2.08 ± 0.34          2.95 ± 1.28          **0.036**
  FM (g)                 18318.14 ± 4069.99   23485.52 ± 7963.91   0.191
  VATM (g)               563.80 ± 147.27      760.08 ± 291.10      0.175
  BMD (*T*-score)        −1.42 ± 0.24         −3.21 ± 0.48         **\<0.001**
                                                                   
                                                                   
  Female                                                            
  *N*                    21                   17                    
  Age (years)            53.38 ± 12.71        52.19 ± 15.86        0.801
  BMI (kg/m^2^)          22.29 ± 3.55         23.48 ± 3.20         0.299
  WC (cm)                81.43 ± 8.08         93.47 ± 7.90         0.727
  WHR                    0.88 ± 0.05          0.88 ± 0. 06         0.869
  SBP (mmHg)             122.19 ± 18.34       127.00 ± 19.21       0.444
  DBP (mmHg)             75.14 ± 14.91        74.38 ± 14.19        0.875
  FPG (mmol/L)           5.53 ± 2.31          6.60 ± 2.17          0.518
  TC (mmol/L)            5.16 ± 1.68          4.26 ± 1.72          0.128
  TG (mmol/L)            1.62 (1.29--2.84)    1.92 (0.94--3.80)    0.529
  HDL-C (mmol/L)         1.35 ± 0.48          1.45 ± 0.32          0.747
  LDL-C (mmol/L)         2.92 ± 0.76          3.37 ± 1.82          0.385
  FM (g)                 16881.19 ± 4155.95   22029.84 ± 7984.97   **0.006**
  VATM (g)               368.76 ± 157.84      608.80 ± 284.91      **\<0.001**
  BMD (*T*-score)        −1.40 ± 0.55         −3.00 ± 0.41         **\<0.001**

Data are expressed as the mean ± standard deviation (SD) or median (interquartile range). The values of parameters showing significant differences between the two groups are marked in red. (*P* \< 0.05). OP: osteoporosis group; N-OP: nonosteoporosis group. *T*-score of BMD was determined for the lumbar spine, at L1-4.

###### 

Correlation between different variables and BMD by univariate analysis.

  Characteristics   Male     Female            
  ----------------- -------- -------- -------- -------------
  Age (years)       −0.099   0.686    −0.330   **0.013**
  BMI (kg/m^2^)     −0.209   0.390    −0.338   **0.041**
  WC (cm)           −0.284   0.238    −0.228   0.174
  WHR               −0.344   0.149    −0.210   0.211
  SBP (mmHg)        0.274    0.257    −0.278   0.095
  DBP (mmHg)        −0.166   −0.397   −0.138   0.416
  FPG (mmol/L)      −0.069   0.823    −0.046   0.822
  TC (mmol/L)       −0.335   0.174    −0.127   0.467
  TG (mmol/L)       −0.253   0.311    −0.196   0.273
  HDL-C (mmol/L)    0.165    0.512    0.040    0.823
  LDL-C (mmol/L)    −0.275   0.269    −0.273   0.118
  FM (g)            −0.186   0.460    −0.408   **\<0.001**
  VATM (g)          −0.433   0.228    −0.506   **\<0.001**

Data are expressed as the mean ± standard deviation (SD) or median (interquartile range). The values of the parameters that showed significant correlation with BMD are marked in red. (*P* \< 0.05). BMD was measured in the ROI of the lumbar spine, at L1−4.

###### 

Independent variables related to BMD in female AGHD patients by multivariate analysis.

  Variables   Unstandardized coefficients   Standardized coefficients   *t*      *P*      
  ----------- ----------------------------- --------------------------- -------- -------- -------------
  VATM        −0.306                        0.074                       −0.418   −4.203   **\<0.001**

BMD values were quantified in the specific ROI of the lumbar spine, at L1−4, by DXA.
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